Taxotere has long been recognized as a key ingredient in many chemotherapy cocktails. Unfortunately, Taxotere has also led to long-term or permanent alopecia and has left many victims unable to regrow hair, after being told that her loss would be temporary. Taxotere has not changed their stance on temporary hair loss, and many new victims are still told that they should experience hair regrowth. This comes into play in a time where Taxotere may experience more use than ever before.
Transparency Market Research estimates that head and neck cancer in North America will reach 342.3 million dollars in Market Revenue. These two types of cancer are growing is substantially, and when it comes to drugs and use, Taxotere is a prime contender. We should all expect to see more Taxotere claims regarding the presence of head and neck cancer increases. The substantial jump in the North American market revenue for head and neck cancer is tied to the rise in prevalence and the surge in healthcare expenses. The pharmaceutical industry and healthcare networks are becoming more expensive, and even with more efficient drugs, the economies are continuing to blossom.
It was way back in 2018 that Sanofi obtained FDA approval for the use of taxes here in patients that have head and neck cancer. Prior to 2018, the Taxotere manufacturer was restricted to their involvement in the treatment of breast cancer, which has resulted in the majority of their alopecia victims being women. It is apparent now that text it to your will hit a much larger market as it will now be used in the treatment of head and neck cancer, along with breast cancer, and many other small types of cancer that it’s obtained approval for over the years. If you have been a victim of the harmful side effects of Taxotere, contact our experienced attorneys at Dalimonte Rueb today.